Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2024 | Importance of minimal sentinel node tumor burden in melanoma staging

Alexander Van Akkooi, MD, PhD, Melanoma Institute Australia, Sydney, Australia, discusses the prognostic significance of minimal sentinel node (SN) tumor burden in melanoma, suggesting it be incorporated into the next American Joint Committee on Cancer (AJCC) staging system. Minimal SN tumor burden can differentiate between high-risk and low-risk stage 3A melanoma, guiding decisions regarding adjuvant treatment. This distinction could help identify patients who would benefit from adjuvant therapy while sparing low-risk patients from unnecessary treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.